Introduction

Joint wear can cause pain, stiffness and reduced mobility. Three approaches people ask about are the ChondroFiller injection, standalone stem cell therapy, and the Liquid Cartilage surgical protocol — which combines the ChondroFiller scaffold with biological adjuncts including, where indicated, the patient's own stem cells. These are not interchangeable: they differ in complexity, invasiveness, and the type of patient they suit. Understanding how each works helps in making informed choices.

Why Joint Wear Matters

Cartilage cushions the joints but has no direct blood supply, which is why it is slow and difficult to recover once worn. If left unaddressed, joint wear can progress. Choosing a suitable option early — and matching the approach to the individual's joint, defect size, and activity level — can ease symptoms and support joint function. No current treatment guarantees cartilage regrowth or reversal of arthritis, so realistic expectations are important from the outset.

What Is the ChondroFiller Injection?

ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold, made by Meidrix Biomedicals in Germany. It is delivered as a non-surgical, single-step, ultrasound-guided injection into the joint — no theatre, no incision, no general anaesthetic. Once in position, the collagen gel self-sets in a few minutes, providing a supportive matrix over worn surfaces. Because it is acellular (cell-free), it does not involve harvesting or preparing biological cells before the procedure.

The ChondroFiller injection is best understood as a joint-preserving, regenerative intervention — not a guaranteed repair, cure or reversal of arthritis. Its collagen composition has biological potential, in that the patient's own progenitor cells can migrate into the scaffold over time. Most people return to normal activities promptly. Evidence from published studies, including a 2023 study of an acellular collagen matrix injection for thumb-base osteoarthritis reporting improvements in pain and grip strength (Corain et al., 2023), supports careful clinical use, though individual responses vary.

Stem Cell Therapy

Stem cell therapy uses mesenchymal stem cells (MSCs) — harvested from the patient's own bone marrow (as bone marrow aspirate concentrate, or BMAC) or from micro-fragmented adipose (fat) tissue. Once collected, the cells are processed and introduced into the joint, with the aim of supporting repair through the cells' trophic and immunomodulatory effects. It is a more complex approach than an injection: it involves harvesting biological material, preparation, and a longer procedural pathway. Outcomes vary and careful assessment is required.

When used as a standalone injection, MSC therapy is a distinct approach from ChondroFiller. Standalone intra-articular MSC injections have a growing evidence base in osteoarthritis and focal cartilage defects, but the clinical literature shows variation in protocols and outcomes. Specialist input is important to determine whether this route is appropriate.

The Liquid Cartilage Surgical Protocol: Combining Both

The Liquid Cartilage protocol — developed by Professor Paul Y. F. Lee — is not a product. It is a keyhole (arthroscopic) surgical technique that uses the ChondroFiller scaffold as its principal material and combines it with biological adjuncts: platelet-rich fibrin (PRF), platelet-rich plasma (PRP), tranexamic acid, and, where indicated, the patient's own MSCs from bone marrow concentrate or micro-fragmented fat tissue.

This is genuine surgery: it is performed in theatre under anaesthetic, using arthroscopic (keyhole) technique. MSCs are used here as an optional adjunct to the scaffold — applied to the prepared defect surface before the ChondroFiller gel is placed — rather than as a standalone injection. The rationale is that MSCs release growth and immunomodulatory factors that may support chondrogenesis and complement the scaffold's regenerative environment. The protocol also includes peri-operative optimisation and a structured rehabilitation programme.

The Liquid Cartilage protocol is suited to larger or more demanding defects, particularly in load-bearing joints such as the knee, hip, shoulder and ankle, where keyhole surgery and a controlled biological environment are needed. It is distinct from the ChondroFiller injection: the scaffold (ChondroFiller) is the same material, but the delivery and biological context are fundamentally different.

Comparing the Three Approaches

The ChondroFiller injection is a single-step, non-surgical procedure suited to accessible lesions and smaller joints, with no cell harvesting and a prompt return to normal activities. Standalone MSC therapy is a more involved, multi-step approach, with variable protocols and outcomes depending on the source of cells and method of delivery. The Liquid Cartilage protocol is a surgical procedure that integrates the ChondroFiller scaffold with biologics and optional MSCs, suited to larger defects and patients who require a more comprehensive regenerative approach under arthroscopic conditions.

The right choice depends on individual factors: the joint involved, defect size, severity of wear, activity level, and whether the patient is a candidate for surgery. Neither the injection nor the surgical protocol benefits from being conflated — they are complementary tools, not synonyms.

Conclusion

ChondroFiller injection, standalone stem cell therapy, and the Liquid Cartilage surgical protocol each have a distinct role in modern joint care. The ChondroFiller injection provides a non-surgical, regenerative option. MSC therapy adds a cellular and paracrine biological layer and can be used alone or, more precisely, as an adjunct within the surgical Liquid Cartilage protocol. At the London Cartilage Clinic, Professor Paul Lee's assessment helps identify which approach — or combination — is appropriate for each patient's joint and goals.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.